SecuritySHOP / Shopify Inc. (82509L107)
Form 6-K Count59
Form SC 13G/A Count19
Form SC 13G Count12
Form SUPPL Count6

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Shopify Inc.


DateFormTitle
2018-06-08 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-05-30 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-05-01 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-05-01 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-04-27 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-04-09 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-03-23 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-02-23 6-K SHOP / Shopify Inc. FORM 6-K (Current Report of Foreign Issuer)
2018-02-23 6-K SHOP / Shopify Inc. FORM 6-K (Current Report of Foreign Issuer)
2018-02-23 SUPPL SHOP / Shopify Inc. SUPPL
2018-02-21 6-K SHOP / Shopify Inc. FORM 6K (Current Report of Foreign Issuer)
2018-02-21 6-K SHOP / Shopify Inc. FORM 6-K (Current Report of Foreign Issuer)
2018-02-21 SUPPL SHOP / Shopify Inc. SUPPL
2018-02-15 40-F SHOP / Shopify Inc. 40-F
2018-02-15 6-K SHOP / Shopify Inc. 6-K (Current Report of Foreign Issuer)
2018-02-14 SC 13G/A SHOP / Shopify Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)
2018-02-14 SC 13G/A SHOP / Shopify Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)
2018-02-16 SC 13G/A SHOP / Shopify Inc. / Klister Credit Corp. - SCHEDULE 13G, AMENDMENT NO. 2 (Passive Investment)
2018-02-16 SC 13G/A SHOP / Shopify Inc. / Lutke Tobias - SCHEDULE 13G, AMENDMENT NO. 2 (Passive Investment)
2018-02-16 SC 13G/A SHOP / Shopify Inc. / Lutke Tobias - SCHEDULE 13G, AMENDMENT NO. 2 (Passive Investment)
2018-02-16 SC 13G/A SHOP / Shopify Inc. / Klister Credit Corp. - SCHEDULE 13G, AMENDMENT NO. 2 (Passive Investment)
2018-02-13 SC 13G/A SHOP / Shopify Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-13 SC 13G/A SHOP / Shopify Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-01-24 SC 13G/A SHOP / Shopify Inc. / FIRSTMARK CAPITAL I, L.P. - SC 13G/A (Passive Investment)
2018-01-24 SC 13G/A SHOP / Shopify Inc. / FIRSTMARK CAPITAL I, L.P. - SC 13G/A (Passive Investment)
2017-11-04 SC 13G Shopify 3G (Passive Acquisition of More Than 5% of Shares)
2017-11-04 SC 13G SHOP / Shopify Inc. / COATUE MANAGEMENT LLC - 3G (Passive Investment)
2017-10-31 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-10-31 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-08-01 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-08-01 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-08-01 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-06-08 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-06-02 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-05-24 6-K Shopify FORM 6-K (Current Report of Foreign Issuer)
2017-05-23 6-K Shopify FORM 6-K (Current Report of Foreign Issuer)
2017-05-19 SUPPL Shopify SUPPL
2017-05-19 6-K Shopify FORM 6-K (Current Report of Foreign Issuer)
2017-05-18 6-K Shopify FORM 6-K (Current Report of Foreign Issuer)
2017-05-18 SUPPL Shopify SUPPL
2017-05-17 F-X Shopify FORM F-X
2017-05-17 F-10 Shopify FORM F-10
2017-05-02 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-05-02 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-05-02 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-03-31 6-K Shopify 6-K (Current Report of Foreign Issuer)
2017-03-21 SC 13G Shopify SC 13G (Passive Acquisition of More Than 5% of Shares)
2017-03-21 SC 13G Shopify SC 13G (Passive Acquisition of More Than 5% of Shares)
2017-02-15 40-F Shopify 40-F
2017-02-15 6-K Shopify 6-K (Current Report of Foreign Issuer)
SHOP : Shopify Stock Analysis and Research Report

2017-11-09 - Asif

Shopify provides the leading cloud-based, multi-channel commerce platform designed for small and medium-sized businesses. Merchants use its software to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts, and marketplaces. As the number of channels over which merchants transact continues to expand, the importance of a multi-channel platform that is both fully integrated and easy to use increases. The Shopify platform provides merchants with a single view of their business and customers across all of their sales channels and enables them to manage products and inventory, process orders and payments, ship orders, build customer relationships and leverage analytics and reporting all from one integrated back office. Commerce transacted over mobile devices continues to grow more rapidly than desktop transactions. For several years Shopify has focused on enabling mobile commerce and its merchants ...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 82509L107